Clovis Oncology, Inc. (CLVS) Insider Gillian C. Ivers-Read Sells 3,000 Shares

Clovis Oncology, Inc. (NASDAQ:CLVS) insider Gillian C. Ivers-Read sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $84.54, for a total value of $253,620.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Clovis Oncology, Inc. (NASDAQ:CLVS) opened at 81.32 on Wednesday. The firm’s market capitalization is $3.97 billion. The company’s 50-day moving average price is $76.90 and its 200 day moving average price is $71.06. Clovis Oncology, Inc. has a 1-year low of $25.81 and a 1-year high of $99.45.

Clovis Oncology (NASDAQ:CLVS) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.02). The business had revenue of $14.62 million during the quarter, compared to the consensus estimate of $13.07 million. During the same quarter in the previous year, the business earned ($2.07) earnings per share. Clovis Oncology’s revenue for the quarter was down 32.5% compared to the same quarter last year. On average, equities analysts anticipate that Clovis Oncology, Inc. will post ($7.55) EPS for the current year.

WARNING: “Clovis Oncology, Inc. (CLVS) Insider Gillian C. Ivers-Read Sells 3,000 Shares” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://ledgergazette.com/2017/10/18/clovis-oncology-inc-clvs-insider-gillian-c-ivers-read-sells-3000-shares-2.html.

A number of analysts have recently issued reports on CLVS shares. Credit Suisse Group set a $107.00 price target on Clovis Oncology and gave the stock a “buy” rating in a research note on Tuesday, July 18th. Cann started coverage on Clovis Oncology in a research note on Thursday, June 22nd. They issued a “market perform” rating on the stock. Gabelli started coverage on Clovis Oncology in a research note on Friday, July 7th. They issued a “buy” rating and a $125.00 price target on the stock. Zacks Investment Research raised Clovis Oncology from a “hold” rating to a “buy” rating and set a $105.00 price target on the stock in a research note on Wednesday, July 12th. Finally, Royal Bank Of Canada started coverage on Clovis Oncology in a research note on Thursday, September 14th. They issued a “sector perform” rating and a $81.00 price target on the stock. Eight analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $86.47.

Several institutional investors have recently made changes to their positions in CLVS. Great West Life Assurance Co. Can grew its stake in shares of Clovis Oncology by 53.7% during the first quarter. Great West Life Assurance Co. Can now owns 4,293 shares of the biopharmaceutical company’s stock valued at $273,000 after acquiring an additional 1,500 shares in the last quarter. UBS Asset Management Americas Inc. grew its stake in shares of Clovis Oncology by 6.9% during the first quarter. UBS Asset Management Americas Inc. now owns 272,092 shares of the biopharmaceutical company’s stock valued at $17,324,000 after acquiring an additional 17,450 shares in the last quarter. Karp Capital Management Corp acquired a new stake in shares of Clovis Oncology during the first quarter valued at about $319,000. Parametric Portfolio Associates LLC grew its stake in shares of Clovis Oncology by 147.6% during the first quarter. Parametric Portfolio Associates LLC now owns 62,458 shares of the biopharmaceutical company’s stock valued at $3,977,000 after acquiring an additional 37,237 shares in the last quarter. Finally, Prudential Financial Inc. acquired a new stake in shares of Clovis Oncology during the first quarter valued at about $242,000. Institutional investors own 98.94% of the company’s stock.

Clovis Oncology Company Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

NASDAQ:CLVS) opened at 81.32 on Wednesday. The firm’s market capitalization is $3.97 billion. The company’s 50-day moving average price is $76.90 and its 200 day moving average price is $71.06. Clovis Oncology, Inc. has a 1-year low of $25.81 and a 1-year high of $99.45.

Clovis Oncology (NASDAQ:CLVS) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.02). The business had revenue of $14.62 million during the quarter, compared to the consensus estimate of $13.07 million. During the same quarter in the previous year, the business earned ($2.07) earnings per share. Clovis Oncology’s revenue for the quarter was down 32.5% compared to the same quarter last year. On average, equities analysts anticipate that Clovis Oncology, Inc. will post ($7.55) EPS for the current year.

WARNING: “Clovis Oncology, Inc. (CLVS) Insider Gillian C. Ivers-Read Sells 3,000 Shares” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://ledgergazette.com/2017/10/18/clovis-oncology-inc-clvs-insider-gillian-c-ivers-read-sells-3000-shares-2.html.

A number of analysts have recently issued reports on CLVS shares. Credit Suisse Group set a $107.00 price target on Clovis Oncology and gave the stock a “buy” rating in a research note on Tuesday, July 18th. Cann started coverage on Clovis Oncology in a research note on Thursday, June 22nd. They issued a “market perform” rating on the stock. Gabelli started coverage on Clovis Oncology in a research note on Friday, July 7th. They issued a “buy” rating and a $125.00 price target on the stock. Zacks Investment Research raised Clovis Oncology from a “hold” rating to a “buy” rating and set a $105.00 price target on the stock in a research note on Wednesday, July 12th. Finally, Royal Bank Of Canada started coverage on Clovis Oncology in a research note on Thursday, September 14th. They issued a “sector perform” rating and a $81.00 price target on the stock. Eight analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $86.47.

Several institutional investors have recently made changes to their positions in CLVS. Great West Life Assurance Co. Can grew its stake in shares of Clovis Oncology by 53.7% during the first quarter. Great West Life Assurance Co. Can now owns 4,293 shares of the biopharmaceutical company’s stock valued at $273,000 after acquiring an additional 1,500 shares in the last quarter. UBS Asset Management Americas Inc. grew its stake in shares of Clovis Oncology by 6.9% during the first quarter. UBS Asset Management Americas Inc. now owns 272,092 shares of the biopharmaceutical company’s stock valued at $17,324,000 after acquiring an additional 17,450 shares in the last quarter. Karp Capital Management Corp acquired a new stake in shares of Clovis Oncology during the first quarter valued at about $319,000. Parametric Portfolio Associates LLC grew its stake in shares of Clovis Oncology by 147.6% during the first quarter. Parametric Portfolio Associates LLC now owns 62,458 shares of the biopharmaceutical company’s stock valued at $3,977,000 after acquiring an additional 37,237 shares in the last quarter. Finally, Prudential Financial Inc. acquired a new stake in shares of Clovis Oncology during the first quarter valued at about $242,000. Institutional investors own 98.94% of the company’s stock.

Clovis Oncology Company Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Insider Buying and Selling by Quarter for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply